SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-24-046137
Filing Date
2024-05-23
Accepted
2024-05-23 11:32:02
Documents
8
Period of Report
2024-05-23

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0206712-6k_akanda.htm 6-K 10651
2 PRESS RELEASE, DATED MAY 21, 2024 ANNOUNCING STOCK CONSOLIDATION ea020671201ex99-1_akanda.htm EX-99.1 7045
3 ARTICLES AND CERTIFICATE OF AMENDMENT OF AKANDA CORP ea020671201ex99-2_akanda.htm EX-99.2 4080
4 GRAPHIC ex99-2_001.jpg GRAPHIC 1003481
5 GRAPHIC ex99-2_002.jpg GRAPHIC 1089516
6 GRAPHIC ex99-2_003.jpg GRAPHIC 921121
7 GRAPHIC ex99-2_004.jpg GRAPHIC 1131355
8 GRAPHIC ex99-2_005.jpg GRAPHIC 964854
  Complete submission text file 0001213900-24-046137.txt   7059581
Mailing Address 77 KING STREET WEST, SUITE 400 C/O DENTONS CANADA LLP TORONTO A6 M5K 0A1
Business Address 1A, 1B LEAROYD ROAD NEW ROMNEY X0 TN28 8XU 442034889514
AKANDA CORP. (Filer) CIK: 0001888014 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-41324 | Film No.: 24976067
SIC: 2833 Medicinal Chemicals & Botanical Products
(CF Office: 03 Life Sciences)